JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson

JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson

Submitted by admin on January 17, 2025 - 11:30am
Source: 
BioPharma Dive
News Tags: 
JPMHC 2025
AbbVie
Eli Lilly
Headline: 
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
snippet: 

AbbVie’s CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained what it got wrong forecasting GLP-1 drug demand.

Do Not Allow Advertisers to Use My Personal information